INmune Bio (NASDAQ:INMB) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a report released on Saturday.

Separately, Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, INmune Bio presently has an average rating of “Hold” and a consensus target price of $8.00.

INmune Bio Price Performance

Shares of INMB opened at $1.43 on Friday. INmune Bio has a 1 year low of $1.09 and a 1 year high of $11.64. The company has a market capitalization of $38.01 million, a price-to-earnings ratio of -0.86 and a beta of 1.04. The business has a 50-day moving average of $1.31 and a 200-day moving average of $1.53.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04.

Institutional Investors Weigh In On INmune Bio

Large investors have recently added to or reduced their stakes in the business. Quadrature Capital Ltd acquired a new stake in INmune Bio during the fourth quarter worth approximately $26,000. Intech Investment Management LLC acquired a new stake in INmune Bio during the second quarter worth approximately $26,000. Cary Street Partners Financial LLC acquired a new stake in INmune Bio during the third quarter worth approximately $29,000. Independent Advisor Alliance acquired a new stake in INmune Bio during the third quarter worth approximately $30,000. Finally, Squarepoint Ops LLC acquired a new stake in INmune Bio during the third quarter worth approximately $30,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.